Table 1.

Characteristics and quality of included studies.

Study	Year	Language	Animal	Sample (T/C)	Route of ADe	Duration (day)	Method	Outcome measure	Conclusion	CASP score
Wang et al. [16]	2011	Chinese	GPa	10/10	ip, iv	14	ASA	IgE, IgG, Hisb, BCc	Negative	14
Zhang et al. [17]	2011	Chinese	GP	6/6	ip, iv	21	ASA, PCA	BC, BSPTd	Negative	16
Lin et al. [26]	2010	Chinese	Rat, GP	19/11	ip, iv	13	ASA, PCA	BC, BSPT	Positive	13
Guo et al. [27]	2011	Chinese	BN rat, GP	4/4	ip, iv	14	ASA	His, BC	Positive	15
Huang et al. [28]	2010	Chinese	GP	6/6	ip, iv	14	ASA	IgE, IgG	Positive	16
Luo et al. [29]	2009	Chinese	Rat, GP	5/5	ip, iv	8	ASA, PCA	BC, BSPT	Negative	13
He et al. [30]	2011	Chinese	Mouse, GP	6/6	iv	14	ASA	IgG, BC	Positive	14
Wu et al. [31]	2010	Chinese	GP	5/5	ip, iv	10	ASA, PCA	BC, BSPT	Negative	14
Li et al. [32]	2008	Chinese	Rat, GP	6/6	ip, iv	14	ASA, PCA	BC, BSPT	Positive	15
Zhang et al. [33]	2010	Chinese	BN rat	6/6	iv	13	ASA	IgE, IgG, BC	Positive	15
Gong et al. [34]	2004	English	mouse	4/4	ip, in	1	ASA	IgE, IgG	Positive	13
Lin et al. [35]	2012	English	Mouse	8/8	iv	11	PLNA	Cellularity, IgG1 AFCs	Positive	16
Liu et al. [36]	2010	English	Mouse	6/6	si	7	PLNA	Cellularity, IgG1 AFCs	Negative	15

^aGuinea pig; ^bhistamine; ^cbehavior change; ^dblue skin patch test; ^eadministration; ip: intraperitoneally; in: intranasally; iv: intravenously; and si: subcutaneous injection.